EverSource Wealth Advisors’s Summit Therapeutics SMMT Stock Holding History

EverSource Wealth Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.37K	Sell	300 -126	-30%	-$2.23K	﹤0.01%	3352
2026 Q1	$8.08K	Buy	426 +287	+206%	+$4.64K	﹤0.01%	3031
2025 Q4	$2.43K	Buy	139 +40	+40%	+$753	﹤0.01%	3424
2025 Q3	$2.04K	Sell	99 -271	-73%	-$6.57K	﹤0.01%	3507
2025 Q2	$7.87K	Sell	370 -83	-18%	-$1.89K	﹤0.01%	2961
2025 Q1	$8.74K	Buy	453 +35	+8%	+$702	﹤0.01%	2178
2024 Q4	$7.46K	Buy	+418	New	+$8.1K	﹤0.01%	2153

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

EverSource Wealth Advisors's SMMT Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Summit Therapeutics (SMMT) stake by 30% in Q2 2026, selling an estimated $2.23K and leaving 300 shares worth $4.37K. The position accounts for ﹤0.01% of the portfolio, ranked #3352.

EverSource Wealth Advisors first reported a position in SMMT in Q4 2024 and has held it in 7 quarters since. The position peaked at $8.74K in Q1 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

EverSource Wealth Advisors held 300 shares of Summit Therapeutics worth $4.37K as of Q2 2026.
EverSource Wealth Advisors sold 126 Summit Therapeutics shares in Q2 2026, an estimated $2.23K.
Summit Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3352 holding.
EverSource Wealth Advisors first reported a position in Summit Therapeutics in Q4 2024 and has held it in 7 quarters since.
EverSource Wealth Advisors's Summit Therapeutics position peaked at $8.74K in Q1 2025.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.